Drug Trial Radar · NCT07387198
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Dec 31, 2029
Study completion Jul 31, 2031
Sponsor
- Lead sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Prof. Gutzmer, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden, Germany; Universität Duisburg-Essen; Regeneron Pharmaceuticals
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Conditions
- Merkel Cell Carcinoma, Stage I
- Merkel Cell Carcinoma, Stage II
- Neoadjuvant Immunotherapy
Interventions
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cyclesDrug
Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.Drug
Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nodal micrometastases-free rateTime frame: up to 36 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Nationales Centrum für Tumorerkrankungen
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Universitätsklinikum Mannheim
Mannheim, Baden-Wurttemberg, Germany · Recruiting
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany · Recruiting
Universitätsklinikum Regensburg
Regensburg, Bavaria, Germany · Recruiting
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany · Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, Germany · Recruiting
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany · Recruiting
Klinikum Bielefeld
Bielefeld, North Rhine-Westphalia, Germany · Recruiting
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany · Recruiting
Johannes Wesling Klinikum Minden
Minden, North Rhine-Westphalia, Germany · Not yet recruiting
Universitätsmedizin Mainz
Mainz, Rhineland-Palatinate, Germany · Recruiting
Helios Klinikum Erfurt
Erfurt, Thuringia, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.